Cameron S Bader, Anna Pavlova, Robert Lowsky, Lori Muffly, Parveen Shiraz, Sally Arai, Laura J Johnston, Andrew R Rezvani, Wen-Kai Weng, David B Miklos, Matthew J Frank, John S Tamaresis, Vaibhav Agrawal, Sushma Bharadwaj, Surbhi Sidana, Judith A Shizuru, Nathaniel B Fernhoff, Amy Putnam, Scott Killian, Bryan J Xie, Robert S Negrin, Everett Meyer
Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for hematological malignancies for which graft-versus-host disease (GVHD) remains a major complication. The use of donor T regulatory cells (Tregs) to prevent GVHD appears promising, including in our previous evaluation of an engineered graft product (T-reg graft) consisting of the timed, sequential infusion of CD34+ hematopoietic stem cells and high-purity Tregs followed by conventional T cells. However, whether immunosuppressive prophylaxis can be removed from this protocol remains unclear...
December 13, 2023: Blood Advances